BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+4.49%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.36B
AUM Growth
+$9.36B
(-3%)
Cap. Flow
+$5.03M
Cap. Flow
% of AUM
0.05%
Top 10 Holdings %
Top 10 Hldgs %
76.51%
Holding
102
New
8
Increased
20
Reduced
5
Closed
7
Top Buys
| 1 |
Insmed
INSM
|
$40.8M |
| 2 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$29.1M |
| 3 |
Candel Therapeutics
CADL
|
$25.9M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$20.8M |
| 5 |
CRISPR Therapeutics
CRSP
|
$18.3M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$192M |
| 2 |
DBVT
DBV Technologies
DBVT
|
$18.1M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$17.6M |
| 4 |
Tango Therapeutics
TNGX
|
$5.78M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$5.31M |
Sector Composition
| 1 | Healthcare | 98.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$16.5B
| $2.12B | 22.68% | 30,739,466 +446 | +0% | +$30.8K |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $1.76B | 18.81% | 9,531,880 -1,037,017 | -10% | -$192M |
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $787M | 8.4% | 42,877,916 | – | – |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $609M | 6.51% | 1,974,590 | – | – |
|
5
Summit Therapeutics
SMMT
$17.6B
| $436M | 4.66% | 24,424,865 | – | – |
|
6
Revolution Medicines
RVMD
$7.1B
| $347M | 3.71% | 7,936,972 +367,882 | +5% | +$16.1M |
|
|
7
Insmed
INSM
$28.8B
| $346M | 3.69% | 5,006,863 +590,945 | +13% | +$40.8M |
|
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $341M | 3.64% | 6,084,249 -314,117 | -5% | -$17.6M |
|
9
Kymera Therapeutics
KYMR
$2.95B
| $241M | 2.58% | 5,995,929 | – | – |
|
10
Kodiak Sciences
KOD
$478M
| $172M | 1.84% | 17,310,490 | – | – |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $164M | 1.76% | 6,155,940 +315,881 | +5% | +$8.43M |
|
|
BCYC
12
Bicycle Therapeutics
BCYC
$511M
| $152M | 1.63% | 10,885,357 +1,485,397 | +16% | +$20.8M |
|
13
Replimune Group
REPL
$422M
| $134M | 1.43% | 11,045,336 | – | – |
|
14
Alkermes
ALKS
$4.78B
| $120M | 1.28% | 4,181,751 | – | – |
|
15
Entrada Therapeutics
TRDA
$208M
| $84.1M | 0.9% | 4,865,819 | – | – |
|
16
AbCellera Biologics
ABCL
$1.25B
| $80.7M | 0.86% | 27,525,640 | – | – |
|
17
Denali Therapeutics
DNLI
$2.23B
| $76.1M | 0.81% | 3,731,695 | – | – |
|
18
Nurix Therapeutics
NRIX
$714M
| $73.1M | 0.78% | 3,882,125 | – | – |
|
19
argenx
ARGX
$43.6B
| $68.8M | 0.74% | 111,904 | – | – |
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| $66.3M | 0.71% | 1,576,114 | – | – |
|
21
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $55.7M | 0.6% | 2,818,323 | – | – |
|
22
Immatics
IMTX
$619M
| $51.7M | 0.55% | 7,275,830 +832,432 | +13% | +$5.92M |
|
|
23
CRISPR Therapeutics
CRSP
$4.71B
| $51.5M | 0.55% | 1,308,011 +464,936 | +55% | +$18.3M |
|
24
Stoke Therapeutics
STOK
$1.08B
| $51.1M | 0.55% | 4,633,838 +265,395 | +6% | +$2.93M |
|
25
Immunocore
IMCR
$1.62B
| $44.7M | 0.48% | 1,515,318 | – | – |
|